Teehan and Lee emphasized progress on reimbursement outside bundled surgical payments. The company exceeded its internal goal and ended 2025 with 102 million covered lives with CMS or commercial coverage outside the surgical bundle, citing payers including Aetna, Cigna, TRICARE, and Humana. Teehan added that the figure climbed to about 110 million within the first month of 2026 and said Pacira intends to continue expanding coverage.Chief Commercial Officer Brendan Teehan said expanding patient and provider ...

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - European shares also experienced gains, with the eurozone's STOXX 600 up by 0.91% and other major indices like Spain's IBEX 35 and London's FTSE 100 also rising [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61% and China's Shanghai Composite rising 0.92% [7] Sector Performance - Utilities sector shares increased by 1.5% on Friday, while health care stocks saw a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] Company News - Rich Sparkle Holdings Ltd shares surged 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares increased by 31% to $8.54 following the appointment of a new CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped 40% to $3.72 due to FDA identified deficiencies [9] - Pacira Biosciences Inc shares fell 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations [10] - The unemployment rate decreased to 4.4%, below expectations of 4.5% [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units [10] - Building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0, the highest since September 2025 [2][10]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - Utilities sector shares increased by 1.5%, while health care stocks experienced a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] European Market Trends - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.91%, Spain's IBEX 35 Index rising 0.01%, London's FTSE 100 increasing by 0.85%, Germany's DAX up by 0.43%, and France's CAC 40 rising by 1.23% [6] Asian Market Trends - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61%, Hong Kong's Hang Seng Index up by 0.32%, China's Shanghai Composite rising by 0.92%, while India's BSE Sensex fell by 0.72% [7] Company-Specific Movements - Rich Sparkle Holdings Ltd saw its shares increase by 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares surged by 31% to $8.54 following the appointment of Everett Cunningham as President and CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped by 40% to $3.72 due to an FDA letter identifying deficiencies [9] - Pacira Biosciences Inc shares fell by 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 [10] - The unemployment rate decreased from 4.5% in November to 4.4%, below expectations [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units, while building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0 in January, the highest since September 2025 [10]

Group 1 - DOMA Perpetual Capital Management owns approximately 6.83% of the outstanding shares of Pacira BioSciences (PCRX) and intends to nominate three independent director candidates at the Company's 2026 annual meeting of stockholders [1] - DOMA asserts that the Company's Board of Directors should pursue an immediate sale of the Company [1] - DOMA criticizes the current level of Executive Compensation and General Spending as exorbitant and unmerited, questioning the Board's fiduciary oversight [1]

Industry Overview - The biotech industry has shown strong performance in 2025 despite a challenging macroeconomic environment, driven by new drug approvals and pipeline progress [1] - Mergers and acquisitions (M&A) surged in 2025, with large pharmaceutical and biotech companies expanding their portfolios through strategic collaborations and acquisitions [2] - The Zacks Biomedical and Genetics industry has outperformed both the Zacks Medical sector and the S&P 500, gaining 22.1% in the last six months compared to 12.5% and 16.5% respectively [18] Key Trends - Innovation and execution are critical, with a focus on high-profile drugs and innovative pipeline development, particularly with the rise of AI technology in drug discovery [6] - Successful commercialization is essential for drug uptake, often requiring collaborations with larger firms due to funding and expertise limitations of smaller biotechs [7] - Pipeline setbacks and potential tariffs pose challenges, as drug development is costly and time-consuming, with many drugs taking years to gain regulatory approval [13][14] Notable Companies - Amicus Therapeutics (FOLD) has performed well, with its lead drug Galafold showing strong demand and recent FDA approval for Pombiliti + Opfolda boosting its portfolio [24] - ANI Pharmaceuticals (ANIP) has seen significant growth in its rare disease franchise, with sales of its ACTH-based injection Cortrophin Gel surging 70% year-over-year [28] - Arcutis Biotherapeutics (ARQT) is focused on treating inflammatory skin diseases, with its lead product Zoryve performing well and expanding its label [32] - Tango Therapeutics is developing precision medicine for oncology, with promising data from its ongoing studies [36] - Pacira BioSciences (PCRX) maintains momentum with its lead drug Exparel and is looking to expand its label further [38]

Core Viewpoint - DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc., is urging the Board to hire bankers and initiate a full sale process for the company due to perceived management underperformance and financial mismanagement [1][2][4]. Financial Performance and Management Concerns - Pacira's management has been criticized for excessive spending, with stock-based compensation projected to be approximately 6% of the company's market capitalization for 2025, exceeding the firm's entire operating income [2][6]. - Year-to-date sales of Zilretta have declined by 2% year over year through Q3, indicating poor business performance [3]. - Revenue growth has been modest at 3% year over year, while expenditures have surged, with R&D costs increasing by 36% and SG&A by 25% year over year [6]. Valuation and Sale Potential - A potential sale could yield a valuation of around $2.7 billion, translating to approximately $66 per share, which is three times the current stock price and represents a reasonable acquisition valuation [4][5]. - The cash flows from Pacira's assets, particularly Exparel, could exceed $10 billion through patent expiration, suggesting significant value under a larger owner [4]. Strategic Recommendations - The company should immediately pursue a sale process, with a target completion date before the end of Q1 2026 [7]. - Cost-cutting strategies must be implemented to enhance shareholder returns, and all new development programs should be put on hold until a sale is explored [12]. - Free cash flow should be prioritized for share buybacks, with a recommendation for a new $300 million buyback program following the completion of the current one [12]. Shareholder Relations and Governance - The Board's actions have been perceived as neglecting shareholder interests, with ongoing dilution of shareholder value through unapproved share issuances [10][11]. - DOMA has been in communication with the Board for over a year, advocating for a shareholder-friendly capital allocation framework, which has only recently begun to materialize [9].

Core Insights - U.S. stock futures showed slight gains, with Dow futures up approximately 0.1% [1] Company Performance - PACCAR Inc reported a significant decline in shares, falling 18.3% to $7.64 in pre-market trading after disappointing third-quarter results [1] - The company's quarterly earnings were $1.12 per share, missing the analyst consensus estimate of $1.17 per share [1] - PACCAR's quarterly sales were reported at $6.107 billion, also below the analyst consensus estimate of $6.371 billion [1] Other Stocks Movement - Neuphoria Therapeutics Inc shares plummeted 65.3% to $5.35 after its AFFIRM-1 trial for social anxiety failed to meet endpoints [4] - Citius Pharmaceuticals Inc shares fell 18.2% to $1.48 following a $6 million registered direct offering announcement [4] - Galapagos NV shares declined 15.4% to $28.99 as the company plans to wind down its Cell Therapy Business [4] - Silvercorp Metals Inc shares decreased by 9.9% to $6.35 in pre-market trading [4] - Other notable declines included Theravance Biopharma Inc down 8.6% to $13.07 and Pacira Biosciences Inc down 8.3% to $21.10 [4]

Summary of Key Points Core Viewpoint - U.S. stock futures showed slight gains, with the Dow futures increasing by approximately 0.1% on Tuesday, while several companies experienced significant declines in pre-market trading due to disappointing earnings or other negative news [1]. Company-Specific Summaries - **PACCAR Inc (NASDAQ:PCAR)**: - Shares fell 18.3% to $7.64 after reporting third-quarter earnings of $1.12 per share, missing the analyst consensus estimate of $1.17 per share. - Quarterly sales were reported at $6.107 billion, also below the consensus estimate of $6.371 billion [1]. - **Neuphoria Therapeutics Inc (NASDAQ:NEUP)**: - Shares dropped 65.3% to $5.35 following the failure of its AFFIRM-1 trial for social anxiety to meet endpoints [4]. - **Citius Pharmaceuticals Inc (NASDAQ:CTXR)**: - Shares decreased by 18.2% to $1.48 after announcing a $6 million registered direct offering [4]. - **Galapagos NV – ADR (NASDAQ:GLPG)**: - Shares declined 15.4% to $28.99 as the company announced plans to wind down its Cell Therapy Business as part of a transformation strategy [4]. - **Silvercorp Metals Inc (NYSE:SVM)**: - Shares fell 9.9% to $6.35 in pre-market trading [4]. - **Theravance Biopharma Inc (NASDAQ:TBPH)**: - Shares decreased by 8.6% to $13.07 [4]. - **Pacira Biosciences Inc (NASDAQ:PCRX)**: - Shares dipped 8.3% to $21.10; the company is set to present new data from a Phase 1 clinical trial for a gene therapy candidate at an upcoming meeting [4]. - **Coeur Mining Inc (NYSE:CDE)**: - Shares fell 8.2% to $20.22 after a previous gain of 5% on Monday [4]. - **Endeavour Silver Corp (NYSE:EXK)**: - Shares declined 8.2% to $8.57 [4]. - **Sibanye Stillwater Ltd (NYSE:SBSW)**: - Shares fell 8.1% to $10.67 [4]. - **First Majestic Silver Corp (NYSE:AG)**: - Shares declined 7.9% to $13.22 [4]. - **Hycroft Mining Holding Corporation (NYSE:HYMC)**: - Shares dipped 7.7% to $8.03 [4]. - **Harmony Gold Mining Company Ltd (NYSE:HMY)**: - Shares declined 6.8% to $18.85 [4]. - **Pan American Silver Corp (NYSE:PAAS)**: - Shares fell 6.6% to $36.80 [4].

Core Insights - Pacira BioSciences, Inc. is presenting new 104-week data for its gene therapy candidate PCRX-201 at the OARSI World Congress, highlighting its commitment to innovative, non-opioid pain therapies [1][4]. Group 1: Product Information - PCRX-201 (enekinragene inzadenovec) is based on a proprietary high-capacity adenovirus vector platform and targets chronic inflammatory processes in knee osteoarthritis, affecting over 14 million individuals in the U.S. [3] - The therapy has shown sustained improvements in knee pain, stiffness, and function for up to two years post-administration, with a favorable safety profile [4]. - PCRX-201 has received RMAT designation from the FDA and ATMP designation from the EMA, marking it as the first gene therapy to achieve such regulatory recognition in knee osteoarthritis [4]. Group 2: Clinical Development - Following promising Phase 1 results, a Phase 2 study (ASCEND study) is currently underway for PCRX-201 to further evaluate its efficacy in treating knee osteoarthritis [5]. Group 3: Company Overview - Pacira specializes in non-opioid pain therapies and has three commercial-stage products: EXPAREL®, ZILRETTA®, and iovera® [6]. - The company is advancing the development of PCRX-201 as a novel treatment option for prevalent diseases like osteoarthritis [6].